Nitrates As an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2012 Apr 25

PMID 22528319

Citations 11

Authors

William E Boden

Aloke V Finn

Dharmesh Patel

W Frank Peacock

Udho Thadani

Franklin H Zimmerman

Affiliations

Soon will be listed here.

Abstract

The goals of optimal medical therapy in patients with stable angina pectoris are to reduce the risk of cardiovascular mortality and future cardiovascular events, improve exercise capacity, and enhance quality of life. Whereas myocardial revascularization is frequently employed in the management of patients with stable angina, a variety of pharmacologic interventions are recommended as part of optimal medical management. The use of short- and rapidly-acting nitrates (eg, sublingual nitroglycerin spray and tablets) is at the core of the therapeutic armamentarium and should be integrated into optimal medical therapy for stable angina along with exercise therapy. The potential clinical implications from these observations are that prophylactic sublingual nitrates, when combined with cardiac rehabilitation, may allow the patient with angina to exercise to a greater functional capacity than without sublingual nitrates.

Citing Articles

The Effect of Nitroglycerin Treatment Initiation Time on Survival in Partial Flap Necrosis: An Experimental Study.

Ustun G, Kaplan G, Ozturk E, Gokoz O, Ozgur F Plast Surg (Oakv). 2024; 32(3):460-467.

PMID: 39104938 PMC: 11298126. DOI: 10.1177/22925503221128984.

Saudi Heart Association (SHA) guidelines for the management of heart failure.

AlHabeeb W, Al-Ayoubi F, Alghalayini K, Al Ghofaili F, Al Hebaishi Y, Al-Jazairi A J Saudi Heart Assoc. 2019; 31(4):204-253.

PMID: 31371908 PMC: 6660461. DOI: 10.1016/j.jsha.2019.06.004.

Acute ingestion of dietary nitrate increases muscle blood flow via local vasodilation during handgrip exercise in young adults.

Richards J, Racine M, Hearon Jr C, Kunkel M, Luckasen G, Larson D Physiol Rep. 2018; 6(2).

PMID: 29380952 PMC: 5789727. DOI: 10.14814/phy2.13572.

Winner of the society for biomaterials young investigator award for the annual meeting of the society for biomaterials, April 11-14, 2018, Atlanta, GA: S-nitrosated poly(propylene sulfide) nanoparticles for enhanced nitric oxide delivery to....

Schudel A, Sestito L, Thomas S J Biomed Mater Res A. 2018; 106(6):1463-1475.

PMID: 29352735 PMC: 5924474. DOI: 10.1002/jbm.a.36348.

The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.

Divakaran S, Loscalzo J J Am Coll Cardiol. 2017; 70(19):2393-2410.

PMID: 29096811 PMC: 5687289. DOI: 10.1016/j.jacc.2017.09.1064.

References

Serruys P, Unger F, Sousa J, JATENE A, Bonnier H, Schonberger J . Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001; 344(15):1117-24. DOI: 10.1056/NEJM200104123441502. View

Lawson W, Hui J, Lang G . Treatment benefit in the enhanced external counterpulsation consortium. Cardiology. 2000; 94(1):31-5. DOI: 10.1159/000007043. View

Smith Jr S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B . AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by.... J Am Coll Cardiol. 2011; 58(23):2432-46. DOI: 10.1016/j.jacc.2011.10.824. View

Terry T, Raravikar K, Chokrungvaranon N, Reaven P . Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2011; 14(1):79-88. DOI: 10.1007/s11886-011-0238-6. View

DeMots H, Glasser S . Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989; 13(4):786-95. DOI: 10.1016/0735-1097(89)90216-7. View

Abrams J, Chatterjee K, Daley J, Deedwania P, Douglas J, Ferguson Jr T . ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of.... Circulation. 2003; 107(1):149-58. DOI: 10.1161/01.cir.0000047041.66447.29. View

Cheitlin M, Hutter Jr A, Brindis R, Ganz P, Kaul S, Russell Jr R . ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999; 33(1):273-82. DOI: 10.1016/s0735-1097(98)00656-1. View

Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K . Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004; 109(11):1371-8. DOI: 10.1161/01.CIR.0000121360.31954.1F. View

Webb D, Muirhead G, Wulff M, Sutton J, Levi R, Dinsmore W . Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000; 36(1):25-31. DOI: 10.1016/s0735-1097(00)00705-1. View

10.

Katritsis D, Ioannidis J . Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005; 111(22):2906-12. DOI: 10.1161/CIRCULATIONAHA.104.521864. View

11.

Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y . Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol. 1998; 32(5):1201-6. DOI: 10.1016/s0735-1097(98)00398-2. View

12.

Arora R, Chou T, Jain D, Fleishman B, Crawford L, McKiernan T . The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999; 33(7):1833-40. DOI: 10.1016/s0735-1097(99)00140-0. View

13.

Thompson P . Exercise prescription and proscription for patients with coronary artery disease. Circulation. 2005; 112(15):2354-63. DOI: 10.1161/CIRCULATIONAHA.104.502591. View

14.

PARKER J, VanKoughnett K, Farrell B . Nitroglycerin lingual spray: clinical efficacy and dose-response relation. Am J Cardiol. 1986; 57(1):1-5. DOI: 10.1016/0002-9149(86)90940-9. View

15.

Axelsson K, Andersson R . Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol. 1983; 88(1):71-9. DOI: 10.1016/0014-2999(83)90393-x. View

16.

Munzel T, Holtz J, Mulsch A, Stewart D, Bassenge E . Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation. 1989; 79(1):188-97. DOI: 10.1161/01.cir.79.1.188. View

17.

Leon A, Franklin B, Costa F, Balady G, Berra K, Stewart K . Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council.... Circulation. 2005; 111(3):369-76. DOI: 10.1161/01.CIR.0000151788.08740.5C. View

18.

Boden W, ORourke R, Teo K, Hartigan P, Maron D, Kostuk W . Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006; 151(6):1173-9. DOI: 10.1016/j.ahj.2005.08.015. View

19.

Kimchi A, Lee G, Amsterdam E, Fujii K, Krieg P, Mason D . Increased exercise tolerance after nitroglycerin oral spray: a new and effective therapeutic modality in angina pectoris. Circulation. 1983; 67(1):124-7. DOI: 10.1161/01.cir.67.1.124. View

20.

Gori T, Burstein J, Ahmed S, Miner S, Al-Hesayen A, Kelly S . Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 2001; 104(10):1119-23. DOI: 10.1161/hc3501.095358. View